Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.
This is the exploratory companion to NIH's larger notice on the same question: how incretin mimetics — GLP-1 agonists, GIP-1 agents and dual GLP-1/GIP-1 drugs — affect cancer risk.
The evidence so far points both ways, with these drugs apparently raising the risk of some obesity-related cancers and lowering the risk of others, and the mechanisms are unexplained.
NIH's second goal is stated along…
Exploratory preclinical and patient-based studies of the mechanisms by which incretin mimetics affect cancer risk, at the scale and risk level of NIH's developmental grant. No clinical trial.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Write proposalHow to Write a Grant Proposal Reviewers Can Score
Learn how to write a grant proposal around reviewer criteria, evidence, work packages, budget logic, and commercialization for deeptech and R&D funding.
More from NIH
All grants from this funder →GREGoRi Data Coordination and Outreach Center
🇺🇸NIH · United States
Funds the one centre that coordinates a rare-disease genomics programme and gets its protocols, data and tools out to everybody else.
GREGoRi Innovation Projects
NIH · United States
Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.
GREGoRi Technology Integration Center
🇺🇸NIH · United States
Funds the centre that turns new molecular methods for rare-disease diagnosis into standards, best practices and a benchmarking dataset.
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases
🇺🇸NIH · United States
Funds studies that watch patients rather than treat them, in bone, joint, rheumatic and skin disease. No intervention allowed.
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61)
🇺🇸NIH · United States
Funds early-stage clinical trials in arthritis, musculoskeletal and skin disease. A trial is compulsory.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01)
NIH · United States
Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.
Similar grants
Browse the directory →
Cancer Mission: First-in-Human Trials for Rare Cancers
🇪🇺European Commission · European Union
Funds €7–9M projects taking biomarker-guided rare-cancer treatments into first-in-human, multicentre phase 1 trials.
CRI Technology Impact Award
CRI · United States
Pays tenure-track researchers up to $600,000 to build unproven cancer immunotherapy technology.
Collaborate with the UK Human Functional Genomics Initiative
🇬🇧MRC · United Kingdom
Test an academic-industry functional-genomics idea and generate early data.
Cancer Mission: Functional Genomics for New Treatments
🇪🇺European Commission · European Union
Funds €7–8M projects that use functional genomics and patient data to uncover precise new targets for difficult-to-treat cancers.
Equitable Cancer Care Economics and Outcomes
🇪🇺European Commission · European Union
Funds three €5–7M projects that make cancer control more equitable, effective and cost-aware for patients and families.
Young Cancer Survivors Quality of Life Network
🇪🇺European Commission · European Union
Funds one €3M coordination action that helps cancer charities and funders improve quality of life for young survivors across Europe.